<DOC>
	<DOCNO>NCT00180115</DOCNO>
	<brief_summary>The AML96 study examines feasibility risk-adapted postremission treatment strategy include relate unrelated allogeneic stem cell transplantation high risk AML patient related allogeneic autologous stem cell transplantation standard risk AML patient multi-center setting . Furthermore randomizes patient intermediate-dose Cytarabine v high-dose Cytarabine within first postremission-course .</brief_summary>
	<brief_title>AML96 - Risk-Adapted Randomized Postremission-Therapy Adult Acute Myeloid Leukemia Patients</brief_title>
	<detailed_description>The AML96 study examines feasibility risk-adapted postremission treatment strategy include relate unrelated allogeneic stem cell transplantation high risk AML patient related allogeneic autologous stem cell transplantation standard risk AML patient multi-center setting . Furthermore randomizes patient intermediate-dose Cytarabine v high-dose Cytarabine within first postremission-course .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>de novo secondary acute myeloid leukemia FAB subtypes M0M2 M4M7 de novo secondary myelodysplastic syndrome FAB subtypes RAEB RAEBT write informed consent severe comorbidities severe uncontrolled complication leukemia previous therapy leukemia/MDS HIVInfection know relevant allergy study medication pregnancy miss write informed consent</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>cytarabine postremission dosage</keyword>
	<keyword>risk adapt treatment strategy</keyword>
	<keyword>allogeneic stem cell transplantation</keyword>
	<keyword>autologous stem cell transplantation</keyword>
</DOC>